Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism
- PMID: 29959155
- DOI: 10.1136/bmjebm-2018-111007
Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism
Conflict of interest statement
Competing interests: None declared.
Comment on
-
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism.N Engl J Med. 2018 Feb 15;378(7):615-624. doi: 10.1056/NEJMoa1711948. Epub 2017 Dec 12. N Engl J Med. 2018. PMID: 29231094 Clinical Trial.
Similar articles
-
Edoxaban for the treatment of cancer associated venous thromboembolism as an alternative to low-molecular-weight-heparin.Intern Emerg Med. 2018 Oct;13(7):1089-1091. doi: 10.1007/s11739-018-1886-y. Epub 2018 Jun 12. Intern Emerg Med. 2018. PMID: 29948831 No abstract available.
-
[Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].Rev Med Liege. 2013 Oct;68(10):548-51. Rev Med Liege. 2013. PMID: 24298731 Clinical Trial. French.
-
Successful Application of Edoxaban in the Treatment of Venous Thromboembolism Recurrence in a Patient with Non-small Cell Lung Cancer after Tumor Shrinkage.Intern Med. 2018 Jun 15;57(12):1769-1772. doi: 10.2169/internalmedicine.9741-17. Epub 2018 Feb 9. Intern Med. 2018. PMID: 29434159 Free PMC article.
-
Edoxaban: A Novel Factor Xa Inhibitor for the Management of Non-valvular Atrial Fibrillation and Venous Thromboembolism.Cardiol Rev. 2016 Jul-Aug;24(4):205-10. doi: 10.1097/CRD.0000000000000104. Cardiol Rev. 2016. PMID: 26991962 Review.
-
Direct factor Xa inhibitor edoxaban: from bench to clinical practice.Expert Rev Hematol. 2015 Dec;8(6):707-25. doi: 10.1586/17474086.2015.1111756. Epub 2015 Nov 11. Expert Rev Hematol. 2015. PMID: 26560872 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources